Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

17
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

28
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

4.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European and Canadian derived risk prediction equations for atherosclerotic cardiovascular disease are valid in Australian patients with genetically confirmed familial hypercholesterolaemia.

Atherosclerosis·2026
Same author

Risk factors for atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis.

Atherosclerosis·2026
Same author

Low-plastic diet and urinary levels of plastic-associated phthalates and bisphenols: the randomized controlled PERTH Trial.

Nature medicine·2026
Same author

The future of triglyceride-regulating therapies and registries.

Current opinion in endocrinology, diabetes, and obesity·2026
Same author

Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries.

Current opinion in endocrinology, diabetes, and obesity·2026
Same author

Association of leukocyte count with atherosclerotic cardiovascular disease in patients with genetically defined familial hypercholesterolaemia.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2025

Related Experiment Video

Updated: May 1, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.7K

Origin and therapy for hypertriglyceridaemia in type 2 diabetes.

Jing Pang1, Dick C Chan1, Gerald F Watts1

  • 1Jing Pang, Dick C Chan, Gerald F Watts, School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6847, Australia.

World Journal of Diabetes
|April 22, 2014
PubMed
Summary

Hypertriglyceridaemia (HTG) in type 2 diabetes increases cardiovascular disease (CVD) risk. Management involves lifestyle changes, statins, and other therapies to reduce residual risk.

Keywords:
DiabetesTherapyTriglyceride

More Related Videos

Fixation and Operational Method for Abdominal Massage in T2DM Mice
05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

845

Related Experiment Videos

Last Updated: May 1, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.7K
Fixation and Operational Method for Abdominal Massage in T2DM Mice
05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

845

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Disorders

Background:

  • Hypertriglyceridaemia (HTG) is a significant cardiovascular disease (CVD) risk factor in type 2 diabetes.
  • Poor glycaemic control and obesity contribute to HTG, persisting despite statin therapy.
  • Residual CVD risk in type 2 diabetes is linked to HTG and atherogenic dyslipidemia.

Purpose of the Study:

  • To review current evidence on managing HTG in type 2 diabetes.
  • To provide practical guidance for clinicians treating HTG in this patient population.
  • To examine emerging therapies and their potential role in HTG management.

Main Methods:

  • Literature review of current evidence.
  • Analysis of treatment guidelines and clinical trial outcomes.
  • Discussion of pharmacotherapy and lifestyle interventions.

Main Results:

  • Lifestyle modifications (diet, exercise) are crucial.
  • Statins are first-line for lipid targets; fibrates, ezetimibe, and n-3 fatty acids are adjunctive for persistent HTG.
  • Niacin's role is questioned; incretin-based therapies require further study. Extreme HTG may need insulin or apheresis.

Conclusions:

  • Comprehensive management of HTG in type 2 diabetes requires a multi-faceted approach.
  • Further research is needed for novel therapies, particularly incretin-based treatments.
  • Clinical endpoint trials are essential for validating new HTG therapies in diabetic patients.